PTC Therapeutics PTCT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $827.11M-53.3% | $1.73B+115% | $1.78B+97.5% | $1.76B+96.0% | $1.77B+91.1% | ||
| $447.15M-15.2% | $455.25M-14.8% | $446.89M-15.8% | $508.15M-4.8% | $527.32M-10.3% | ||
| $352.37M+14.2% | $347.14M+15.4% | $334.95M+14.5% | $324.36M+8.1% | $308.6M-3.2% | ||
| $32.53M+150% | $24.74M-59.3% | $18.7M-86.1% | $14.2M-92.5% | $13.01M-94.5% | ||
| $885.44M-16.4% | $863.72M-22.1% | $1B-3.1% | $1.05B-4.7% | $1.06B-18.2% | ||
| $885.44M-16.4% | $863.72M-22.1% | $1B-3.1% | $1.05B-4.7% | $1.06B-18.2% | ||
| $13.02M-98.2% | $938.28M+410% | $775.9M+653% | $718.37M+452% | $713.11M+291% | ||
| 1.6%-38.7pp | 54.2%+91.7pp | 43.6%+59.2pp | 40.7%+63.3pp | 40.2%+80.5pp | ||
| -$167.17M-4.3% | -$152.23M+8.8% | -$138.1M+18.9% | -$147.12M+6.1% | -$160.25M-12.3% | ||
| -$10.17M-652% | -$18.09M-376% | $3.31M-80.1% | -$5.06M-191% | -$1.35M-177% | ||
| —— | —— | $741M+274% | $666.09M+235% | $651.41M+201% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $751.72M+266% | $629.17M+231% | $594.84M+203% | ||
| —— | —— | $8.56+244% | $6.97+210% | $6.51+185% | ||
| —— | —— | $9.61+262% | $8.02+227% | $7.56+198% | ||
| 336.1M+6.1% | 340M+10.7% | 328.5M+7.7% | 318.3M+4.9% | 316.9M+5.1% | ||
| 318.7M+3.3% | 314.3M+2.4% | 311.6M+2.2% | 310M+2.2% | 308.6M+2.4% | ||
| $62.18M+12.0% | $47.01M-18.1% | $56.35M-2.0% | $51.41M-18.4% | $55.52M-13.1% | ||
| $8.78M— | $9.63M— | —— | —— | —— | ||
| -$167.17M-4.3% | -$152.23M+8.8% | -$138.1M+18.9% | -$147.12M+6.1% | -$160.25M-12.3% | ||
| $32.53M+150% | $24.74M-59.3% | $18.7M-86.1% | $14.2M-92.5% | $13.01M-94.5% | ||
| —— | —— | —— | —— | $5.18M-96.0% | ||
| —— | —— | —— | —— | —— | ||
| -$10.17M-652% | -$18.09M-376% | $3.31M-80.1% | -$5.06M-191% | -$1.35M-177% | ||
| $827.11M-53.3% | $1.73B+115% | $1.78B+97.5% | $1.76B+96.0% | $1.77B+91.1% | ||
| $13.02M-98.2% | $938.28M+410% | $775.9M+653% | $718.37M+452% | $713.11M+291% | ||
| $60.03M-91.9% | $977.1M+531% | $808.57M+8,481% | $746.42M+55,686% | $740.6M+697% | ||
| $60.03M-91.9% | $977.1M+531% | $808.57M+8,481% | $746.42M+55,686% | $740.6M+697% | ||
| 7.3%-34.5pp | 56.5%+84.6pp | 45.4%+44.4pp | 42.3%+42.1pp | 41.8%+55.1pp | ||
| $13.02M-98.2% | $938.28M+410% | $775.9M+653% | $718.37M+452% | $713.11M+291% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is PTC Therapeutics's revenue?
- PTC Therapeutics (PTCT) generated $827.1M in revenue over the trailing twelve months, down 53.3% year over year.
- Is PTC Therapeutics profitable?
- PTC Therapeutics reported $814.8M in net income over the trailing twelve months, a 42.3% net margin.
- What are PTC Therapeutics's profit margins?
- Gross margin is 96.0% and operating margin is 1.6%, with a 42.3% net margin.
- What is PTC Therapeutics's earnings per share?
- PTC Therapeutics's diluted EPS over the trailing twelve months is $9.38.
- Where does PTC Therapeutics's income statement data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
